Patents by Inventor William C. Fanslow, III
William C. Fanslow, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230235024Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to large-scale production of therapeutic molecules containing such variant Fc.Type: ApplicationFiled: July 14, 2022Publication date: July 27, 2023Applicant: Amgen Inc.Inventors: Zhimei DU, Pranhitha REDDY, Randal B. BASS, Feng HE, William C. FANSLOW, III, Yuling ZHANG, Da REN, Randall R. KETCHEM
-
Patent number: 11427627Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to largescale production of therapeutic molecules containing such variant Fc. Described herein are compositions and methods to improve glycosylation maturation of and to minimize the culture process-dependent effects of Fc-containing molecules, e.g., Fc-fusion molecules and antibodies. Creating single and multiple amino acid substitutions within the Fc domain with the aim to improve high mannose processing and glycosylation maturation.Type: GrantFiled: September 5, 2014Date of Patent: August 30, 2022Assignee: Amgen Inc.Inventors: Zhimei Du, Pranhitha Reddy, Randal B. Bass, Feng He, William C. Fanslow, III, Yuling Zhang, Da Ren, Randal R. Ketchem
-
Publication number: 20220267446Abstract: Provided herein are mixtures of antibodies comprising an anti-hCTLA4 antibody and an anti-hPD1 antibody, polynucleotides encoding such mixtures and host cells containing the polynucleotides, methods of making and using such mixtures, and pharmaceutical compositions comprising such a mixture of antibodies or (a) polynucleotide(s) encoding the mixture.Type: ApplicationFiled: February 18, 2022Publication date: August 25, 2022Inventors: Zhi LIU, William C. FANSLOW, III, Wei YAN, David L. TREIBER
-
Patent number: 10465009Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.Type: GrantFiled: December 5, 2013Date of Patent: November 5, 2019Assignee: Amgen Inc.Inventors: Richard J. Armitage, Michelle Blake, William C. Fanslow, III, Jason Charles O'Neill, Gunasekaran Kannan, Jiangchun Xu, Mark Edward Tometsko, Zhulun Wang, Athena Sudom
-
Patent number: 10220090Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.Type: GrantFiled: December 11, 2015Date of Patent: March 5, 2019Assignee: Amgen Inc.Inventors: Richard J. Armitage, Michelle Blake, William C. Fanslow, III, Jason Charles O'Neill, Gunasekaran Kannan, Jiangchun Xu, Mark Edward Tometsko
-
Publication number: 20190008974Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.Type: ApplicationFiled: December 11, 2015Publication date: January 10, 2019Applicant: Amgen Inc.Inventors: Richard J. ARMITAGE, Michelle BLAKE, William C. FANSLOW, III, Jason Charles O'NEILL, Gunasekaran KANNAN, Jiangchun XU, Mark Edward TOMETSKO
-
Publication number: 20170165373Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.Type: ApplicationFiled: December 11, 2015Publication date: June 15, 2017Applicant: Amgen Inc.Inventors: Richard J. ARMITAGE, Michelle BLAKE, William C. FANSLOW, III, Jason Charles O'NEILL, Gunasekaran KANNAN, Jiangchun XU, Mark Edward TOMETSKO
-
Patent number: 9574008Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.Type: GrantFiled: February 10, 2015Date of Patent: February 21, 2017Assignee: AMGEN INC.Inventors: John M. Delaney, William C. Fanslow, III, Chadwick T. King
-
Publication number: 20160207980Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to largescale production of therapeutic molecules containing such variant Fc. Described herein are compositions and methods to improve glycosylation maturation of and to minimize the culture process-dependent effects of Fc-containing molecules, e.g., Fc-fusion molecules and antibodies. Creating single and multiple amino acid substitutions within the Fc domain with the aim to improve high mannose processing and glycosylation maturation.Type: ApplicationFiled: September 5, 2014Publication date: July 21, 2016Applicant: AMGEN INC.Inventors: Zhimei DU, Pranhitha REDDY, Randal B. BASS, Feng HE, William C. FANSLOW, III, Yuling ZHANG, Da REN, Randal R. KETCHEM
-
Patent number: 9243058Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.Type: GrantFiled: December 5, 2013Date of Patent: January 26, 2016Assignee: Amgen, Inc.Inventors: Richard J. Armitage, Michelle Blake, William C. Fanslow, III, Jason Charles O'Neill, Gunasekaran Kannan, Jiangchun Xu, Mark Edward Tometsko
-
Publication number: 20150344583Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.Type: ApplicationFiled: December 5, 2013Publication date: December 3, 2015Inventors: Richard J. ARMITAGE, Michelle BLAKE, William C. FANSLOW, III, Jason Charles O'NEILL, Gunasekaran KANNAN, Jiangchun XU, Mark Edward TOMETSKO, Zhulun WANG, Athena SUDOM
-
Publication number: 20150218284Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.Type: ApplicationFiled: February 10, 2015Publication date: August 6, 2015Inventors: John M. DELANEY, William C. FANSLOW, III, Chadwick T. KING
-
Publication number: 20140161828Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.Type: ApplicationFiled: December 5, 2013Publication date: June 12, 2014Applicant: AMGEN INC.Inventors: Richard J. ARMITAGE, Michelle BLAKE, William C. FANSLOW, III, Jason Charles O'NEILL, Gunasekaran KANNAN, Jiangchun XU, Mark Edward TOMETSKO
-
Patent number: 8414895Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: October 6, 2010Date of Patent: April 9, 2013Assignee: Immunex CorporationInventors: Kristine M. Kim, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
-
Patent number: 8410252Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: August 24, 2010Date of Patent: April 2, 2013Assignee: Immunex CorporationInventors: David J Cosman, Jurgen Mullberg, William C Fanslow, III, Marek Z Kubin, Richard J Armitage
-
Publication number: 20110281789Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: ApplicationFiled: August 24, 2010Publication date: November 17, 2011Applicant: IMMUNEX CORPORATIONInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Publication number: 20110020267Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: ApplicationFiled: October 6, 2010Publication date: January 27, 2011Inventors: Kristine M. Kim, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
-
Patent number: 7833697Abstract: The present invention provides stem cells characterized as having the ability to renew and the ability to give rise to endothelial and/or endothelial-like cells, methods of isolating such stem cells and methods of use thereof. Also provided are progeny cells derived from the stem cells of the invention.Type: GrantFiled: December 20, 2002Date of Patent: November 16, 2010Assignee: Immunex CorporationInventors: William C. Fanslow, III, Anne-Marie C. Rousseau, Thomas O. Daniel
-
Patent number: 7829675Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: January 16, 2009Date of Patent: November 9, 2010Assignee: Immunex CorporationInventors: Kristine M. Kim, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
-
Patent number: 7807796Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: August 4, 2008Date of Patent: October 5, 2010Assignee: Immunex CorporationInventors: David J Cosman, Jurgen Mullberg, William C Fanslow, III, Marek Z Kubin, Richard J Armitage